ACS Chemical Neuroscience p. 638 - 661 (2017)
Update date:2022-08-15
Topics:
Sánchez-Arias, Juan A.
Rabal, Obdulia
Cuadrado-Tejedor, Mar
De Miguel, Irene
Pérez-González, Marta
Ugarte, Ana
Sáez, Elena
Espelosin, Maria
Ursua, Susana
Haizhong, Tan
Wei, Wu
Musheng, Xu
Garcia-Osta, Ana
Oyarzabal, Julen
A novel systems therapeutics approach, involving simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylase (HDAC), has been validated as a potentially novel therapeutic strategy for the treatment of Alzheimer’s disease (AD). First-in-class dual inhibitors bearing a sildenafil core have been very recently reported, and the lead molecule 7 has proven this strategy in AD animal models. Because scaffolds may play a critical role in primary activities and ADME-Tox profiling as well as on intellectual property, we have explored alternative scaffolds (vardenafil- and tadalafil-based cores) and evaluated their impact on critical parameters such as primary activities, permeability, toxicity, and in vivo (pharmacokinetics and functional response in hippocampus) to identify a potential alternative lead molecule bearing a different chemotype for in vivo testing.
View MoreFUJIAN SHANSHUI CHEMICAL CORP.LTD.
Contact:+86-151-59920036
Address:Jinqiao Gareden, jo@fj-xinyi.com
Zipont chem(wuhan)Tech co.,Ltd
Contact:+86-27-87587198
Address:wuhan
Shandong Bolode Bio-Technology Co., LTD
Contact:+86-0531-58966870
Address:136 Jingyi Road,Huaiyin District,Jinan,Shandong,China
Xiamen XM-Innovation Chemical Co., Ltd
Contact:+86-592-3216205
Address:Unit Q, 11/F, No.1 Office Building, Wuyuan Bay Business Center, Huli District, Xiamen City, Fujian Province, P.R.C
Suqian Ruixing Chemical Co., Ltd.
Contact:+86-527-80805666(总机);84836008(销售)
Address:3 Jingsilu, Zone north, Hubin Xincheng Development Park, Suqian, China
Doi:10.1016/j.bmcl.2007.05.073
(2007)Doi:10.1002/chem.201201874
(2012)Doi:10.1063/1.462776
(1992)Doi:10.1021/ja016798j
(2002)Doi:10.1002/cctc.201900882
(2019)Doi:10.14233/ajchem.2020.22669
(2020)